查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387441

磊晶药物和诊断技术市场报告：2030 年趋势、预测和竞争分析

Epigenetic Drug and Diagnostic Technology Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

磊晶药物与诊断技术的趋势与预测

至2030年，全球磊晶药物和诊断技术市场预计将达到277亿美元，2024年至2030年的年复合成长率为19.2%。该市场的主要驱动力是癌症和神经系统疾病等慢性病盛行率的上升、人口老化的迅速加剧以及新磊晶药物和诊断技术的创新。全球磊晶医学和诊断技术市场的未来充满希望，肿瘤学和非肿瘤学市场充满机会。

磊晶药物和诊断技术市场洞察

Lucintel 预计 DNMT 由于其广泛的可用性，在预测期内仍将是一个更大的细分市场。

在这个市场中，由于癌症的高成长和癌症死亡人数的增加，肿瘤学将继续成为较大的细分市场。

由于拥有成熟的医疗设施和快速增长的老年人口，北美在预测期内可能仍然是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球磊晶药物与诊断技术市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球磊晶医学和诊断技术市场趋势（2018-2023）和预测（2024-2030）
  • 按治疗类型分類的全球磊晶药物和诊断技术市场
    • HDAC
    • DNMT
  • 按技术分類的全球磊晶医学和诊断技术市场
    • DNA甲基化
    • 组蛋白甲基化
    • 组蛋白乙酰化
    • 大非编码RNA
    • 微小RNA的修饰
    • 染色质结构
  • 全球磊晶医学和诊断技术市场（按应用）
    • 肿瘤学
    • 非肿瘤学

第4章2018-2030年分地区市场趋势及预测分析

  • 按地区分類的全球磊晶药物和诊断技术市场
  • 北美磊晶药物与诊断技术市场
  • 欧洲磊晶医学与诊断技术市场
  • 亚太磊晶医学与诊断技术市场
  • 其他区域磊晶药物和诊断技术市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球磊晶药物和诊断技术市场成长机会（按治疗类型）
    • 按技术分類的全球磊晶药物和诊断技术市场的成长机会
    • 全球磊晶药物和诊断技术市场的成长机会（按应用）
    • 全球磊晶药物和诊断技术市场成长机会（按地区）
  • 全球磊晶医学及诊断技术市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球磊晶医学和诊断技术市场的容量
    • 全球磊晶医学和诊断技术市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen
简介目录

Epigenetic Drug and Diagnostic Technology Trends and Forecast

The future of the global epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets. The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030 with a CAGR of 19.2% from 2024 to 2030. The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

A more than 150-page report is developed to help in your business decisions.

Epigenetic Drug and Diagnostic Technology by Segment

The study includes a forecast for the global epigenetic drug and diagnostic technology by type of therapy, technology, application, and region.

Epigenetic Drug and Diagnostic Technology Market by Type of Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • HDAC
  • DNMT

Epigenetic Drug and Diagnostic Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • Large Noncoding RNA
  • Microrna Modification
  • Chromatin Structures

Epigenetic Drug and Diagnostic Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Non-Oncology

Epigenetic Drug and Diagnostic Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Epigenetic Drug and Diagnostic Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies epigenetic drug and diagnostic technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the epigenetic drug and diagnostic technology companies profiled in this report include-

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen

Epigenetic Drug and Diagnostic Technology Market Insights

Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Within this market, oncology will remain the larger segment due to high growth of cancer and rising number of deaths caused by cancer.

North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Features of the Global Epigenetic Drug and Diagnostic Technology Market

Market Size Estimates: Epigenetic drug and diagnostic technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Epigenetic drug and diagnostic technology market size by type of therapy, technology, application, and region in terms of value ($B).

Regional Analysis: Epigenetic drug and diagnostic technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type of therapy, technologies, applications, and regions for the epigenetic drug and diagnostic technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the epigenetic drug and diagnostic technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the epigenetic drug and diagnostic technology market size?

Answer: The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030.

Q2. What is the growth forecast for epigenetic drug and diagnostic technology market?

Answer: The global epigenetic drug and diagnostic technology market is expected to grow with a CAGR of 19.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the epigenetic drug and diagnostic technology market?

Answer: The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

Q4. What are the major segments for epigenetic drug and diagnostic technology market?

Answer: The future of the epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets.

Q5. Who are the key epigenetic drug and diagnostic technology market companies?

Answer: Some of the key epigenetic drug and diagnostic technology companies are as follows:

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen

Q6. Which epigenetic drug and diagnostic technology market segment will be the largest in future?

Answer: Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Q7. In epigenetic drug and diagnostic technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the epigenetic drug and diagnostic technology market by type of therapy (HDAC and DNMT), technology (DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microrna modification, and chromatin structures), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Epigenetic Drug and Diagnostic Technology Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Epigenetic Drug and Diagnostic Technology Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
    • 3.3.1: HDAC
    • 3.3.2: DNMT
  • 3.4: Global Epigenetic Drug and Diagnostic Technology Market by Technology
    • 3.4.1: DNA Methylation
    • 3.4.2: Histone Methylation
    • 3.4.3: Histone Acetylation
    • 3.4.4: Large Noncoding RNA
    • 3.4.5: Microrna Modification
    • 3.4.6: Chromatin Structures
  • 3.5: Global Epigenetic Drug and Diagnostic Technology Market by Application
    • 3.5.1: Oncology
    • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Epigenetic Drug and Diagnostic Technology Market by Region
  • 4.2: North American Epigenetic Drug and Diagnostic Technology Market
    • 4.2.2: North American Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.3: European Epigenetic Drug and Diagnostic Technology Market
    • 4.3.1: European Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.3.2: European Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.4: APAC Epigenetic Drug and Diagnostic Technology Market
    • 4.4.1: APAC Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.4.2: APAC Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.5: ROW Epigenetic Drug and Diagnostic Technology Market
    • 4.5.1: ROW Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.5.2: ROW Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
    • 6.1.2: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Technology
    • 6.1.3: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Application
    • 6.1.4: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Region
  • 6.2: Emerging Trends in the Global Epigenetic Drug and Diagnostic Technology Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Epigenetic Drug and Diagnostic Technology Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Epigenetic Drug and Diagnostic Technology Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Roche Diagnostics
  • 7.2: Thermo Fisher Scientific
  • 7.3: Eisai
  • 7.4: Novartis
  • 7.5: Illumina
  • 7.6: Merck Sharp & Dohme
  • 7.7: Qiagen